本次活动充分发挥高校作为科技创新策源地的重要作用，通过搭建产学研深度融合与校企精准对接 平台，推动科技创新与产业创新双向奔赴，促进高校科技成果尽快落地转化为现实生产力，服务区域经 济高质量发展。当日，东北大学、哈尔滨工业大学、吉林大学、沈阳理工大学、沈阳工程学院5所高校 与东北华能、华润电力等企业，就战略性金属材料及产品产业化项目、新能源消纳与深度脱碳项目等签 订合作协议，落地转化9项重大科技成果。 活动由教育部高等学校科学研究发展中心、辽宁省教育厅、沈阳市人民政府等单位共同主办，以开 放、创新、融合、发展为主题，汇聚全国90余所高校，300余名高校科研团队、技术经理人代表，500余 家企业、科技服务机构参加活动。活动中共推介发布新一代信息技术、先进制造、新能源、生物制造、 现代农业、智能文创六大领域高校高价值科技成果700余项，展示大学生创新创业作品300余件，组织近 百位高校专业技术经理人现场推介成果，撮合交易。 9月16日，第三届辽宁校企协同科技创新伙伴行动暨高校科技成果东北地区对接活动在沈阳市新世 界博览馆举行。活动包括高校科技成果超市体验、企业需求高校竞标、大学生创新创业市集等内容，一 批高校科技成 ...

Group 1: Company Overview and Market Position - COFCO Biotech is the only company approved to produce D-Alulose using specific enzymes in China, indicating a unique market position [1][2] - The company is actively expanding its D-Alulose market presence through self-built capacity and third-party collaborations [1][4] Group 2: Financial Performance and Stock Issuance - The non-public offering price is set at 9.38 CNY per share, while the current market price is 6.14 CNY, reflecting a significant discount [2][7] - The company aims to enhance shareholder value through strategic collaborations that exceed the capital value, compensating for the dilution of existing shareholders' equity [2][7] Group 3: Project Development and Future Plans - Current projects include a new starch sugar production facility with an annual capacity of 550,000 tons and a 30,000-ton lactide project, with ongoing expansions in Chengdu [2][7] - The D-Alulose project is expected to enter the food application market, with ongoing updates provided through regular reports and interactive platforms [1][4] Group 4: Regulatory and Market Environment - The company's strategy aligns with national policies promoting a unified market and reducing competition through technological upgrades rather than price competition [5][6] - The company has established a market value management system to enhance investment value and protect investor rights amid a significant market cap reduction of 5.9 billion CNY over seven years [7]

【SynBioCon】 获 悉，近日，国内绿色科技 企业 北京塑新科技有限公司 （以 下简称 "塑新科 技"）宣布完成 pre-A 轮和 pre-A+ 轮融资，总额达数千万元人民币。 新一轮资金将主要用于 推 进 万吨级生物酶法再生 PET 产线建设与技术迭代 。目前，公司已启动后续融资计划。 在全球塑料污染日益严峻的背景下，塑新科技致力于通过生物酶技术实现高分子材料的高效降解与循 环利用，尤其聚焦 PET 再生领域。据统计，全球每年塑料废弃物总量近 4 亿吨，传统物理和化学 回收方式存在效率低、成本高、二次污染等问题。塑新科技依托自主研发的 AI 增强酶设计平台和规 模化酶库，实现了生物降解酶在耐酸性、稳定性和催化效率等方面的突破，显著降低了工业量产难度 与综合成本。 公司团队具备 "产学投"复合背景。核心技术负责人 董维亮 来自国内重点高校 南京工业大学 ，深 耕生物工程领域； CEO 向科炜 具备连续 成功 创业及高分子材料产业经验，曾推动多个 年销过亿 的 产品从研发到市场化全过程； CFO 齐云达 拥有投资行业背景，擅长资源整合与资本战略。这一 组合为技术转化和商业落地提供了坚实保障。 目前，塑新科 ...

Core Viewpoint - The development prospects for the private economy in the Hainan Free Trade Port are broad and promising, with significant opportunities for private enterprises and entrepreneurs to thrive as the port construction progresses [1]. Group 1: Private Enterprises in Hainan - As of June 30, 2023, there are 360.44 million private business entities in Hainan, accounting for 97.54% of the province's total business entities, with 937,200 private enterprises contributing nearly 60% of the GDP and about 90% of employment [2]. - Private enterprises are seen as a crucial driving force in the construction of the Hainan Free Trade Port, enhancing overall strength, innovation capability, and market competitiveness [2]. Group 2: Legislative Support for Private Economy - The "Several Provisions on Promoting the Development of the Private Economy in Hainan Free Trade Port" was implemented on July 30, 2023, aimed at optimizing the development environment for private enterprises and ensuring fair market competition [3]. - This legislation is the first local regulation following the national "Private Economy Promotion Law" and consists of 29 articles focusing on fair competition, policy empowerment, and financial support [3]. Group 3: Policy Empowerment for Private Economy - The provisions encourage private economic organizations to participate in key industries such as tourism, modern services, high-tech industries, and tropical agriculture, and to engage in significant project construction [4]. - The regulations also support technological innovation, urging private enterprises to increase R&D investment in strategic emerging industries and establish mechanisms for collaboration with research institutions [4]. Group 4: Internationalization and Trade Support - The provisions require relevant departments to enhance service and regulatory collaboration, providing one-stop services for cross-border trade and investment, and supporting private enterprises in international expansion [5]. - Hainan's policies, including "zero tariffs" and "low tax rates," are expected to reduce corporate tax burdens and investment costs, thereby attracting more investors [6].

9月12日-13日，2025生物制造全链条标准化研讨会暨生物智造标准化国际联盟第一次大会在北京昌平开 幕。来自国内外的百余位科技及标准化专家学者、政府代表和企业界人士齐聚一堂，他们的目标非常明 确：为方兴未艾的生物制造产业制定全球统一的"规则之尺"。 "我们现在只能做企业标准，但没有行业标准和国际标准，在市场上推行时会遇到一些阻碍问题。"连静 静说。这也证明，即便技术实现了突破，其新产品在缺乏公认"尺子"衡量的情况下，难以获得国际市场 的广泛认可，标准的缺位，已成为制约科技成果产业化的关键瓶颈。 成为"规则策源地"，把"尺子"攥在自己手里 "所以，谁制定'尺子'，谁就会引领整个产业的发展。"北京未来科学城管理委员会医药健康产业处副处 长郭玉东告诉记者，"现在很多的'尺子'都掌握在外国人手里。我们要从制造业大国变成制造业强国， 就要把'尺子'攥到自己手里。" 记者了解到，本次大会汇聚了二十余位国际标准组织主席及全球顶尖专家，共识已然达成：将以标准化 为抓手，率先在微生物基因组数据、多模态数据接口、数据管理利用等基础领域，推动3-5项由中国主 导的国际标准诞生。 而此次大会由昌平区依托中国科学院微生物所联合举办， ...

下一步，未来科学城集团将以此大会为契机，持续完善园区服务体系，通过提供标准化空间、建设加速培育体系、搭建创新生态服务平台，充分运用自 有及政府引导基金，吸引更多高成长性、创新力强的合成生物制造项目转化落地，助力昌平区打造北京市合成生物制造先行先试示范区，为北京乃至全 国的生物制造产业发展注入新的活力，推动全球生物制造产业走向更加安全、高效、可持续的发展轨道。 新华财经北京9月13日电（记者董道勇）作为全球新一轮科技革命和产业变革的战略制高点，生物制造是一种以细胞、活性分子和生物材料为基本成形单 元，实现生物组织及器官的生理属性、结构及机能的体外制造的技术。 9月12日-13日，2025生物制造全链条标准化研讨会暨生物智造标准化国际联盟第一次大会在位于北京市昌平区的未来科学城举办。来自国内外的百余位 科技及标准化专家学者、政府代表和企业界人士，共同探讨生物制造全链条国际标准建设，谋划推动产业高质量发展。 2024年，我国生物制造领域取得快速进展，尤其在微生物合成用于绿色化工和药物研发、增材制造技术用于个性化医疗植入物的生产以及生物材料在能 源和环境领域的应用等方面表现突出。生物制造不仅为低碳经济的构建提供了动力 ...

Group 1 - The provincial government emphasizes the importance of digital transformation and industrial collaboration in manufacturing to support high-quality development in Heilongjiang [1][5] - The focus is on enhancing technological innovation and promoting the "smart transformation and digital upgrade" of the manufacturing sector [1][5] - Key projects such as vertical casting machines and fiber composite material laying equipment are being examined to understand their impact on technological advancement and industrial growth [3][5] Group 2 - The government highlights the need for innovation-driven development to improve manufacturing capabilities and competitiveness in the equipment manufacturing industry [7] - There is a call to strengthen industrial collaboration and enhance the resilience of supply chains to create a high-end equipment manufacturing cluster [7] - The importance of market expansion and improving product variety, quality, and branding is stressed to increase local supply capabilities [7] Group 3 - The government is focusing on the deep processing of agricultural products and the development of biomanufacturing industry clusters [9] - There is an emphasis on providing robust support from local governments and relevant departments to enhance service efficiency for enterprises [9] - The aim is to create a market-oriented, law-based, and internationalized first-class business environment to facilitate digital and intelligent upgrades for companies [9]

今年以来，在产业各方的协同努力下，我国生物制造技术快速突破并加快向各领域渗透，政策支持体系 日益完善，产业发展前景更加广阔，展现出生物制造作为未来产业的巨大潜力和强劲动力。 华东理工大学生物反应器工程全国重点实验室叶邦策团队构建基于肿瘤微环境响应的自调控智能工程菌 系统，实现了对肿瘤组织的精准靶向定植；全国首个正式投产的天然产物生物制造示范线在上海化学工 业区启动；吉林化纤（000420）年产3.5万吨生物质人造丝项目一期2万吨生产线全面达产…… 生物制造加速向各领域渗透 今年上半年，伴随基因工程、合成生物学等核心技术的快速进步，生物制造越来越广泛地应用到医药、 材料、农业等多个领域，带动传统生产方式的变革与发展。 在生物医药领域，中国科学院刘陈立团队以沙门氏菌为底盘细胞，利用实体肿瘤细胞相对正常细胞的缺 氧环境，开发了新型的抗肿瘤菌株DB1，能精准识别肿瘤并激活免疫系统；中国科学院刘光慧团队用合 成生物学手段对干细胞的长寿基因通路进行重编程，提高了抗氧化和祖细胞抗衰老等能力…… 在生物基材料领域，上海蓝晶微生物科技有限公司创始人张浩千团队自主研发的生物混动技术体系，使 聚羟基脂肪酸酯（PHA）单位产量与碳源 ...

/生物制造产业社群/ 让上下游聚在一起, 未来食农、绿色化工、大健康、美妆个护 等产业同行❤️↓ SynBio团队 | 天津大学|齐崴教授|尤生萍副研究 员|张聪强研究| PET酶 解技术 【SynBioCon】 获 悉，近期， 天津大学齐崴教授 、尤生萍副研究员 团队 与 新加坡科技研究局 （ A*STAR ） 张聪强研究员团队 在生物技术领域 知名 期刊《 Biotechnology Advances 》（影 响因子： 12.5 ，中科院一区 TOP ）上合作 发表题为 " Bio-upcycling PET waste: Advances in enzymatic hydrolysis and biosynthesis of value-added products " 的综述论文。 在全球塑料污染日益严峻的背景下，聚对苯二甲酸乙二醇酯（ PET ）作为应用最广泛的工程塑料之 一，其大规模生产与低效回收之间的矛盾愈发突出。 2022 年全球 PET 产量已达 8810 万吨，然 而其天然 耐 降解特性与不当回收管理导致大量 PET 废弃物堆积，不仅造成资源浪费，更对生态环 境和人类健康构成严重威胁。传统 ...

Core Insights - The article highlights the unique path taken by Yikole Biotechnology in the biomanufacturing sector, emphasizing its successful transition from research to large-scale production, which is critical for survival in the industry [1][2]. Group 1: Company Overview - Yikole has launched nearly 20 products in its ten years of operation, achieving significant market share in several of them [1]. - The company recently completed a strategic investment of 450 million yuan from Guotou Juli [1]. Group 2: Technological Innovation - Yikole has developed a platform-based technology system that integrates design, modification, and application, breaking the "R&D to mass production" bottleneck [2]. - The company has built a library of over 60,000 enzyme entities covering 20 types of industrial reactions, enabling rapid adaptation to different product development needs [2]. Group 3: Product Development - Yikole is the only company approved by the National Health Commission to produce high-end sweetener Steviol Glycoside M using enzyme conversion methods, with new sugar-reduced beverages already launched [3]. - The company has also become one of the first licensed producers of human milk oligosaccharides in China, with its 2'-fucosyllactose receiving approval in October 2023 [3]. Group 4: Market Strategy - Yikole's management team consists of experienced professionals from the biomanufacturing sector, ensuring a unified vision for addressing industry pain points and creating marketable products [4]. - The company is focusing on upstream raw materials like methanol and carbon dioxide, which are not constrained by arable land or food supply, aiming to reduce production costs and promote a green transition [5]. - Yikole is forming joint ventures with leading companies in specific fields to leverage their market resources and facilitate product commercialization [5].